The Japan osteoarthritis therapeutics market was valued at USD 431.30 Million in 2025, driven by the rising prevalence of osteoarthritis across the region. The market is anticipated to grow at a CAGR of 5.80% during the forecast period of 2026-2035, with the values likely to reach USD 757.94 Million by 2035. The market is further driven by the aging population, growing demand for biologic treatments, and advancements in regenerative therapies. The increased adoption of non-surgical options is expected to fuel market growth in the forecast period.
Base Year
Historical Period
Forecast Period
The market trends include a preference non-opioid solution. For instance, in August 2022, Grünenthal partnered with Shionogi, licensing RTX for knee osteoarthritis pain treatment in Japan.
The Japan osteoarthritis therapeutics market is driven by an aging population, increasing healthcare investments, and rising demand for non-opioid treatments, creating opportunities for advanced therapies like RTX to address unmet needs.
The market growth is driven by a growing shift towards personalized treatments, enhanced focus on non-invasive therapies, and the adoption of advanced biologics, which are revolutionizing pain management for osteoarthritis patients in Japan.
Compound Annual Growth Rate
5.8%
Value in USD Million
2026-2035
*this image is indicative*
Osteoarthritis therapeutics focus on managing the symptoms and progression of the disease by addressing pain, inflammation, and joint degeneration. The treatment landscape includes a variety of options such as pharmacological therapies, physical therapy, and surgical interventions, all aimed at improving mobility and enhancing the quality of life for individuals suffering from this chronic condition. The market is anticipated to reach USD 757.94 Million by 2035, driven by an aging population and increasing healthcare needs. The ongoing innovation in treatment options, coupled with the expanding healthcare infrastructure in Japan, will continue to shape the market dynamics in the coming years.
Rising Prevalence of Osteoarthritis to Augment the Market Value
The rising prevalence of osteoarthritis among Japan’s aging population serves as a key driver for market growth. According to Toshinaga Tsuji et al., approximately 43% of men and 62% of women aged 40 years and older suffer from knee-related osteoarthritis, while 17% are affected by shoulder osteoarthritis. This widespread occurrence is significantly increasing demand for effective therapeutic solutions, thereby fueling market expansion.
The market is experiencing several trends, notably the introduction of innovative therapies and an increasing shift toward long-acting, single-injection treatment options:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Drug Class
Market Breakup by Dosage Form
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Segmentation Based on Type to Witness Substantial Growth
Based on type, the market is segmented into knee osteoarthritis, hip osteoarthritis, spinal osteoarthritis, hand osteoarthritis, and others. Knee osteoarthritis is projected to dominate the market due to Japan’s rapidly aging population, where individuals over 65 years are more prone to degenerative knee conditions. The rising burden of obesity and sedentary lifestyles further contributes to the increasing incidence of knee-related osteoarthritis, prompting greater demand for targeted treatments.
NSAIDs are Expected to Lead the Japan Osteoarthritis Therapeutics Market by Drug Class
Various type of drug classes including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, hyaluronic acid injections, and other analgesics are available in the market. Among these, NSAIDs are expected to lead the segment, owing to their role as the first-line pharmacologic treatment for osteoarthritis in Japan. Their accessibility, affordability, and ability to reduce inflammation and relieve pain in mild to moderate cases make them a preferred option among both clinicians and patients.
The key features of the market report comprise clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Established in 1947 and headquartered in Tokyo, Japan, Seikagaku Corporation is a key player in the market. In April 2025, the company entered a strategic partnership with Ono Pharmaceutical Co., Ltd. to co-develop and market Gel-One, a cross-linked hyaluronate intra-articular injection aimed at providing long-term pain relief for osteoarthritis. Currently in Phase III clinical trials for knee and hip osteoarthritis, Seikagaku's commitment to non-surgical, sustained treatments for joint degeneration underscores its leadership in advancing innovative therapeutic solutions across Japan.
Ono Pharmaceutical Co., Ltd., founded in 1717 and based in Osaka, Japan, has entered a significant collaboration with Seikagaku Corporation to co-develop and market Gel-One, a cross-linked hyaluronate injection for osteoarthritis. This treatment, currently in Phase III clinical trials for knee and hip osteoarthritis in Japan, aligns with Ono's dedication to addressing the nation's growing osteoarthritis challenges. By partnering with Seikagaku, Ono strengthens its position in the expanding osteoarthritis therapeutics market, aiming to improve patient outcomes and accelerate access to innovative treatments.
Shionogi & Co., Ltd., headquartered in Osaka, Japan, is a leader in pharmaceutical innovation. In 2022, the company entered into a licensing agreement with Grünenthal GmbH to commercialize injectable resiniferatoxin (RTX) in Japan for osteoarthritis pain treatment. RTX, a TRPV1 agonist, offers long-lasting pain relief, marking a significant advance in osteoarthritis management. Shionogi's strategic focus on CNS diseases and pain aligns with this development, addressing a significant unmet need in the Japanese market.
Medipost Co., Ltd., specializes in stem cell therapies. Its flagship product, Cartistem, is an allogeneic mesenchymal stem cell therapy derived from umbilical cord blood, designed for knee osteoarthritis treatment. In Japan, Medipost successfully initiated Phase 3 clinical trials for Cartistem in 2023, following approval from the Pharmaceuticals and Medical Devices Agency (PMDA). The company aims to expand its global footprint through partnerships and co-commercialization opportunities.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer Inc., Mitsubishi Tanabe Pharma Corporation, Eli Lilly and Company, Sanofi S.A., and Novartis AG.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Drug Class |
|
| Breakup by Dosage Form |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share